The coexpression of EphB4 and EphrinB2 is associated with poor prognosis in HER2-positive breast cancer [Retraction]
Authors Li X, Song C, Huang G, Sun S, Qiao J, Zhao J, Zhao Z, Li M
Received 26 April 2017
Accepted for publication 26 April 2017
Published 4 May 2017 Volume 2017:10 Pages 2425—2426
Li X, Song C, Huang G, Sun S, Qiao J, Zhao J, Zhao Z, Li M. The coexpression of EphB4 and EphrinB2 is associated with poor prognosis in HER2-positive breast cancer. OncoTargets and Therapy. 2017;10:1735–1742.
The authors have advised us of concerns about the specificity of the primary antibody which have resulted in misleading and false results.
This Retraction relates to this paper
This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.Download Article [PDF]